BioWorld

Feb. 17, 2006

View Archived Issues

Tysabri Events For Biogen Idec Overshadow Year-End Figures

Despite a rocky year that began with the Tysabri market withdrawal, Biogen Idec Inc. reported strong fourth-quarter and full-year 2005 earnings driven by robust Avonex sales and lower expenses. (BioWorld Today) Read More

Onyx, Bayer Move Nexavar Into Yet Another Phase III

Read More

QLT’s BPH Drug Fails To Show Efficacy In Phase II

Read More

Pandemic, Defense VC Fund: $200M For Fighting Avian Flu

Read More

Holiday Notice

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More